当前位置:
X-MOL 学术
›
Nat. Rev. Drug. Disc.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
FDA approves first drug for primary progressive multiple sclerosis
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2017-04-28 00:00:00 , DOI: 10.1038/nrd.2017.88 Asher Mullard
Nature Reviews Drug Discovery ( IF 122.7 ) Pub Date : 2017-04-28 00:00:00 , DOI: 10.1038/nrd.2017.88 Asher Mullard
The FDA approved Roche's ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis (PPMS), wrapping up a 40-year development history for the anti-CD20 monoclonal antibody (mAb). This is the first drug approval for PPMS, a form of the neurodegenerative disease that
中文翻译:
FDA批准首个用于原发性进行性多发性硬化症的药物
FDA批准罗氏ocrelizumab用于治疗复发性和原发性进行性多发性硬化症(PPMS),总结了抗CD20单克隆抗体(mAb)已有40年的开发历史。这是PPMS的首个药物批准,PPMS是一种神经退行性疾病,
更新日期:2017-05-18
中文翻译:
FDA批准首个用于原发性进行性多发性硬化症的药物
FDA批准罗氏ocrelizumab用于治疗复发性和原发性进行性多发性硬化症(PPMS),总结了抗CD20单克隆抗体(mAb)已有40年的开发历史。这是PPMS的首个药物批准,PPMS是一种神经退行性疾病,